Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00359307 · ClinicalTrials.gov registry record
Genetic Factors in Atherosclerosis
A clinical trial of Atherosclerosis, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 1,888
- Enrollment target
- 1
- Study location
NCT00359307: Completed study of Atherosclerosis, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00359307 is a study of Atherosclerosis that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 1,888 participants, above the 1,038-participant average among 69 other Atherosclerosis trials with a reported enrollment target (82% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00359307, a study of Atherosclerosis, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 1,888 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to identify genes associated with certain risk factors for atherosclerosis (hardening of the arteries) and its consequences, such as development of coronary artery disease, heart attack, other blood vessel disease and stroke. People enrolled in the Framingham Heart Study in Framingham, Massachusetts, are eligible to participate in this study. They will undergo a medical history, including review of their medical records and a family history; evaluation of memory and mood; breathing test and electrocardiogram (EKG); blood and urine tests, including blood sample collection for DNA (genetic) testing; evaluation of gait (walking), balance and hand grip strength; and hearing test. They will also fill out questionnaires on their eating habits and general health. Any patients who may suffer a stroke during the study will be examined during their hospitalization and at 3, 6, 12, and 24 months after the stroke. This examination includes a neurological evaluation, assessment of ability to perform daily living tasks and, possibly, magnetic resonance imaging (MRI) of the brain, a test that uses a strong magnetic field and radio waves to produce pictures of the brain.
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,888 participants |
| Start Date | 2000-06-08 |
| Est. Completion | 2013-03-21 |
What the finished NCT00359307 record still lists
NCT00359307 is an observational study that tracks outcomes without assigning an intervention. Its 1,888 participants enrollment target places it among the larger protocols in the corpus, above the 1,038-participant average among 69 other Atherosclerosis trials with a reported enrollment target (82% higher).
The record links to 1 condition, with Atherosclerosis appearing as the primary indexed condition, and to 0 interventions.
NCT00359307 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00359307 about?
NCT00359307 is a clinical study titled "Genetic Factors in Atherosclerosis". The purpose of this study is to identify genes associated with certain risk factors for atherosclerosis (hardening of the arteries) and its consequences, such as development of coronary artery disease, heart attack, other blood vessel disease and stroke. People enrolled in the Framingham Heart Stud...
What is the current status of trial NCT00359307?
This trial is currently completed. The enrollment target is 1,888 participants. The study started on 2000-06-08. Estimated completion is 2013-03-21.
What conditions does trial NCT00359307 study?
This clinical trial studies the following conditions: Atherosclerosis.
Who is sponsoring clinical trial NCT00359307?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00359307 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00359307's enrollment target sits among peer trials
1,888 11th of 69 higher than 59 of 69 other Atherosclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atherosclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
RECRUITING · Phase 4
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
-
PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]
RECRUITING · NA
-
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
RECRUITING
-
New Heart Imaging Techniques to Evaluate Possible Heart Disease
RECRUITING · NA
-
Natural History of Uncommon Dyslipidemias, Rare Lipid Disorders and Unusual Atherosclerotic Conditions
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06438640 · 1,881 participants · NA
Evaluating a Strategy to Improve Pre-Anesthesia Care Discussions (My Anesthesia Choice-Hip Fracture)
- NCT07308717 · 1,896 participants · Phase 4
Gabapentin And Breast Surgery Decision Architecture Randomization Trial (GABS-DART) Protocol
- NCT03729180 · 1,900 participants · NA
The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery
- NCT05712200 · 1,900 participants · Phase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI